Ulker Tok, MD
Rheumatology · Tucson, AZNPI 1073580924
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 1,187 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $4,118 and has fallen 51.4% since, to $2,000 in 2025.
Across 1,187 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Amgen$5K
- Pfizer$3K
- UCB, Inc.$1K
- GSK$972
- Sanofi$696
- plus $5K from 33 others
What the payments were for
- Food & beverage$19,61599%
- Education$991%
- Gifts$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 256 | $4,529 |
| Amgen(2 entities) | 285 | $4,503 |
| Pfizer | 238 | $2,951 |
| UCB, Inc. | 49 | $1,127 |
| GSK | 61 | $972 |
| Sanofi | 32 | $696 |
| Lilly USA, LLC | 44 | $692 |
| E.r. Squibb & Sons, L.L.C. | 36 | $617 |
| Organon | 29 | $537 |
| AstraZeneca(2 entities) | 23 | $511 |
| Novartis | 21 | $409 |
| Bristol Myers Squibb | 19 | $387 |
| Genentech USA, Inc. | 12 | $239 |
| Radius Health, Inc. | 12 | $212 |
| Johnson & Johnson(2 entities) | 13 | $180 |
| Actelion Pharmaceuticals US, Inc. | 5 | $147 |
| Boehringer Ingelheim | 7 | $134 |
| Aurinia Pharma U.S., Inc. | 6 | $97 |
| Mallinckrodt Hospital Products Inc. | 3 | $95 |
| Sandoz | 5 | $92 |
| Octapharma USA, Inc. | 2 | $65 |
| Fresenius Kabi USA, LLC | 2 | $63 |
| Biocon Biologics Inc | 3 | $60 |
| Mallinckrodt Enterprises LLC | 2 | $47 |
| Celltrion USA Inc. | 2 | $45 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $41 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Sobi, Inc | 1 | $26 |
| Bio Products Laboratory USA, Inc. | 4 | $25 |
| Hikma Pharmaceuticals USA | 2 | $24 |
| Tonix Medicines, Inc. | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Mylan Institutional Inc. | 1 | $22 |
| Almatica Pharma LLC | 1 | $20 |
| Ascend Therapeutics US, LLC | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Tersera Therapeutics LLC | 1 | $16 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,733 in reported general payments places this provider in the 75th percentile of 102 rheumatology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 376 | $3,380,034 |
| Enbrel SureclickEtanercept | 195 | $1,538,579 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 106 | $828,907 |
| Xeljanz XrTofacitinib Citrate | 127 | $780,001 |
| RinvoqUpadacitinib | 82 | $549,383 |
| Orencia ClickjectAbatacept | 70 | $432,611 |
| Cyltezo(Cf) PenAdalimumab-Adbm | 46 | $331,195 |
| BenlystaBelimumab | 70 | $237,993 |
| Humira(Cf)Adalimumab | 13 | $160,875 |
| ProliaDenosumab | 66 | $116,401 |
| OrenciaAbatacept/Maltose | 22 | $111,455 |
| InflectraInfliximab-Dyyb | 30 | $106,512 |
| XeljanzTofacitinib Citrate | 13 | $75,643 |
| KevzaraSarilumab | 15 | $64,058 |
| RemicadeInfliximab | 15 | $55,876 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $4,529 | $710,25895 claims |
| GSKBenlysta | $972 | $237,99370 claims |
| PfizerInflectra, Xeljanz | $2,951 | $182,15543 claims |
| AmgenProlia | $4,503 | $116,40166 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $617 | $111,45522 claims |
| SanofiKevzara | $696 | $64,05815 claims |
| Johnson & JohnsonRemicade | $180 | $55,87615 claims |
| Lilly USA, LLCOlumiant | $692 | $33,97012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 102 rheumatology providers in Arizona.
Other rheumatology in Tucson
- Michael MaricicTucson$110K
- Augusto PosadasTucson$81K
- Romy CabacunganTucson$26K
- Jeffrey LoomerTucson$21K
- Jawad BilalTucson$19K
- Chian KwohTucson$12K
- Berchman VazTucson$9K
- James EvansTucson$5K
- Shannon HoweTucson$4K
- Albert RedfordTucson$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.